Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory Disease and Cancer Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IL12RB2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL12RB2 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View IL12RB2 Products |
| Gene Delivery | IL12RB2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and functional signaling assays. |
View IL12RB2 Products |
| Benchmark Ab | Anti-IL12RB2 Recombinant Antibody Recombinant positive control for binding and flow cytometry validation. |
View IL12RB2 Products |
| Validator | IL12RB2 siRNA Set For target knockdown validation in primary T cells or NK cells. |
View IL12RB2 Products |
| Related Target A | IL12RB1 The co-receptor subunit required to form the high-affinity functional IL-12 receptor complex. |
View IL12RB1 Products |
| Related Target B | IL12 The heterodimeric cytokine ligand (p35/p40) that initiates signaling through IL12RB1/IL12RB2. |
View IL12 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity to ensure cross-reactivity profiling |
| Subfamily counter screening (e.g., IL23R, IL12RB1) | Homolog panel proteins strictly verified by mass spectrometry and sequence analysis to prevent off-target binding |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included to establish assay baselines |
| False Positives | Validated siRNA included for specificity checks and target knockdown verification |
Live IL12RB2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL12RB2 therapeutics is intensifying, with major players shifting focus from traditional systemic cytokine administration to targeted monoclonal antibodies, bispecifics, and cell therapies. As first-generation therapies targeting the IL-12 pathway (such as p40 inhibitors) reach mature clinical stages, the next wave of R&D is targeting the specific modulation of IL12RB2 to selectively tune Th1 and NK cell responses while avoiding the severe toxicities historically associated with systemic IL-12 therapy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Agonist/Antagonist) | Biotech Innovators, Academic Medical Centers | Autoimmune Diseases (Crohn's, Psoriasis), Oncology | Receptor assembly assays (Requires high-purity IL12RB2 and IL12RB1 ECD-Fc) |
| Bispecific / Multi-specific Antibodies | Global Biopharma, Immuno-oncology Specialists | Solid Tumors, Hematological Malignancies | Dual-targeting validation (Need cross-reactive antibodies and ortholog proteins) |
| CAR-T / Cell Therapy (IL12R-engineered) | Cell Therapy Pioneers | Refractory Tumors, Immunotherapy Enhancement | Cell line construction and transduction validation (Need Lentivirus for stable expression) |